• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

杂环类药物对细胞色素 P4503A4 的抑制动力学确定了一般的顺序多步结合过程。

Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.

机构信息

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

出版信息

J Biol Chem. 2021 Jan-Jun;296:100223. doi: 10.1074/jbc.RA120.016855. Epub 2020 Dec 25.

DOI:10.1074/jbc.RA120.016855
PMID:33449875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7948456/
Abstract

Cytochrome P450 (P450) 3A4 is the enzyme most involved in the metabolism of drugs and can also oxidize numerous steroids. This enzyme is also involved in one-half of pharmacokinetic drug-drug interactions, but details of the exact mechanisms of P450 3A4 inhibition are still unclear in many cases. Ketoconazole, clotrimazole, ritonavir, indinavir, and itraconazole are strong inhibitors; analysis of the kinetics of reversal of inhibition with the model substrate 7-benzoyl quinoline showed lag phases in several cases, consistent with multiple structures of P450 3A4 inhibitor complexes. Lags in the onset of inhibition were observed when inhibitors were added to P450 3A4 in 7-benzoyl quinoline O-debenzylation reactions, and similar patterns were observed for inhibition of testosterone 6β-hydroxylation by ritonavir and indinavir. Upon mixing with inhibitors, P450 3A4 showed rapid binding as judged by a spectral shift with at least partial high-spin iron character, followed by a slower conversion to a low-spin iron-nitrogen complex. The changes were best described by two intermediate complexes, one being a partial high-spin form and the second another intermediate, with half-lives of seconds. The kinetics could be modeled in a system involving initial loose binding of inhibitor, followed by a slow step leading to a tighter complex on a multisecond time scale. Although some more complex possibilities cannot be dismissed, these results describe a system in which conformationally distinct forms of P450 3A4 bind inhibitors rapidly and two distinct P450-inhibitor complexes exist en route to the final enzyme-inhibitor complex with full inhibitory activity.

摘要

细胞色素 P450(P450)3A4 是参与药物代谢的主要酶,也可以氧化许多甾体。这种酶还参与了一半的药代动力学药物相互作用,但在许多情况下,P450 3A4 抑制的确切机制的细节仍不清楚。酮康唑、克霉唑、利托那韦、茚地那韦和伊曲康唑是强抑制剂;用模型底物 7-苯甲酰喹啉分析抑制逆转的动力学表明,在几种情况下存在滞后阶段,与 P450 3A4 抑制剂复合物的多种结构一致。当抑制剂被添加到 7-苯甲酰喹啉 O-去苄化反应中的 P450 3A4 中时,观察到抑制的起始滞后,并且对于利托那韦和茚地那韦抑制睾酮 6β-羟化也观察到类似的模式。在与抑制剂混合时,P450 3A4 表现出快速结合,这可以通过光谱移位来判断,至少部分具有高自旋铁特性,随后缓慢转化为低自旋铁-氮络合物。这些变化最好用两个中间络合物来描述,一个是部分高自旋形式,另一个是另一个中间络合物,半衰期为秒。动力学可以用一个系统来建模,该系统涉及抑制剂的初始松散结合,然后是一个缓慢的步骤,导致在多毫秒时间尺度上形成更紧密的络合物。尽管不能排除一些更复杂的可能性,但这些结果描述了一个系统,其中 P450 3A4 的构象不同的形式快速结合抑制剂,并且在最终的酶-抑制剂复合物具有完全抑制活性之前存在两种不同的 P450-抑制剂络合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/c0321ba80262/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/3af9d815db67/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/7c6e914172f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/2746a021bd2b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/9a6a0c32eba2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/4291a4c1a106/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/6ed45d1930c1/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/03b52210bdee/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/a27673730c47/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/ca0a41235af4/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/9b46d6096cb1/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/c0321ba80262/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/3af9d815db67/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/7c6e914172f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/2746a021bd2b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/9a6a0c32eba2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/4291a4c1a106/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/6ed45d1930c1/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/03b52210bdee/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/a27673730c47/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/ca0a41235af4/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/9b46d6096cb1/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f018/7948456/c0321ba80262/gr11.jpg

相似文献

1
Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.杂环类药物对细胞色素 P4503A4 的抑制动力学确定了一般的顺序多步结合过程。
J Biol Chem. 2021 Jan-Jun;296:100223. doi: 10.1074/jbc.RA120.016855. Epub 2020 Dec 25.
2
Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops.通过工程环来调节人 P450 3A4 和 B. megaterium 还原酶之间的相互作用。
Biochim Biophys Acta Proteins Proteom. 2018 Jan;1866(1):116-125. doi: 10.1016/j.bbapap.2017.07.009. Epub 2017 Jul 19.
3
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.抑制剂与人细胞色素 P45017A1 的逐步结合及对雄激素生物合成的快速抑制动力学。
J Biol Chem. 2021 Aug;297(2):100969. doi: 10.1016/j.jbc.2021.100969. Epub 2021 Jul 15.
4
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.五种人类免疫缺陷病毒(HIV)蛋白酶抑制剂在体外对细胞色素P450 3A4、3A5和3A7的差异抑制作用。
Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85. doi: 10.1111/j.1742-7843.2006.pto_249.x.
5
N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.细胞色素P450 3A4对N-杂环卡宾的捕获
Mol Pharmacol. 2016 Jul;90(1):42-51. doi: 10.1124/mol.116.103721. Epub 2016 Apr 28.
6
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.在药物相互作用研究中,利托那韦作为细胞色素P450 - 3A的指标性抑制剂,是酮康唑的最佳替代药物。
Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Epub 2015 Jun 1.
7
Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.利托那韦类似物作为一种用于解读细胞色素P450 3A4抑制机制的探针。
Curr Top Med Chem. 2014;14(11):1348-55. doi: 10.2174/1568026614666140506120647.
8
The xenobiotic inhibitor profile of cytochrome P4502C8.细胞色素P4502C8的外源性物质抑制特征
Br J Clin Pharmacol. 2000 Dec;50(6):573-80. doi: 10.1046/j.1365-2125.2000.00316.x.
9
Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.吡啶取代的去羟肌苷是一种比利托那韦更有效的细胞色素 P450 3A4 抑制剂。
J Med Chem. 2013 May 9;56(9):3733-41. doi: 10.1021/jm400288z. Epub 2013 Apr 26.
10
Elucidation of distinct ligand binding sites for cytochrome P450 3A4.细胞色素P450 3A4不同配体结合位点的阐明。
Biochemistry. 2000 May 23;39(20):5929-39. doi: 10.1021/bi992765t.

引用本文的文献

1
Liver fatty acid binding protein FABP1 transfers substrates to cytochrome P450 4A11 for catalysis.肝脏脂肪酸结合蛋白FABP1将底物转移至细胞色素P450 4A11以进行催化。
J Biol Chem. 2025 Feb;301(2):108168. doi: 10.1016/j.jbc.2025.108168. Epub 2025 Jan 8.
2
Secondary Binding Site of CYP17A1 in Enhanced Sampling Simulations.CYP17A1 的二级结合位点在增强采样模拟中的研究
J Chem Inf Model. 2024 Oct 14;64(19):7679-7686. doi: 10.1021/acs.jcim.4c01293. Epub 2024 Sep 26.
3
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.

本文引用的文献

1
Kinetic Evidence for an Induced Fit Mechanism in the Binding of the Substrate Camphor by Cytochrome P450.细胞色素P450与底物樟脑结合中诱导契合机制的动力学证据。
ACS Catal. 2021 Jan 15;11(2):639-649. doi: 10.1021/acscatal.0c04455. Epub 2020 Dec 29.
2
Methylene Oxidation of Alkyl Sulfates by Cytochrome P450 and a Role for Conformational Selection in Substrate Recognition.细胞色素P450催化烷基硫酸盐的亚甲基氧化及构象选择在底物识别中的作用
ACS Catal. 2020 May 1;10(9):5008-5022. doi: 10.1021/acscatal.0c00677. Epub 2020 Apr 2.
3
Inhibition and induction of CYP enzymes in humans: an update.
在健康志愿者中存在强 CYP3A4 抑制剂(酮康唑)或诱导剂(利福平)时奥瑞巴替尼(HQP1351)的药代动力学。
Clin Transl Sci. 2024 Sep;17(9):e70021. doi: 10.1111/cts.70021.
4
Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.个体人类细胞色素 P450 酶在药物代谢中的作用。
Pharmacol Rev. 2024 Oct 16;76(6):1104-1132. doi: 10.1124/pharmrev.124.001173.
5
IK Channel-Independent Effects of Clotrimazole and Senicapoc on Cancer Cells Viability and Migration.克霉唑和银杏酸对癌细胞活力和迁移的 IK 通道非依赖性影响。
Int J Mol Sci. 2023 Nov 14;24(22):16285. doi: 10.3390/ijms242216285.
6
Steroid 17α-hydroxylase/17, 20-lyase (cytochrome P450 17A1).甾体 17α-羟化酶/17,20-裂合酶(细胞色素 P45017A1)。
Methods Enzymol. 2023;689:39-63. doi: 10.1016/bs.mie.2023.04.001. Epub 2023 Apr 25.
7
Differential Effects of Clotrimazole on X-Ray Crystal Structures of Human Cytochromes P450 3A5 and 3A4.克霉唑对人细胞色素 P450 3A5 和 3A4 X 射线晶体结构的差异影响。
Drug Metab Dispos. 2023 Dec;51(12):1642-1650. doi: 10.1124/dmd.123.001464. Epub 2023 Sep 28.
8
An Insight into the Metabolism of 2,5-Disubstituted Monotetrazole Bearing Bisphenol Structures: Emerging Bisphenol A Structural Congeners.双酚结构取代的 2,5-二取代单四唑代谢研究:新兴的双酚 A 结构类似物。
Molecules. 2023 Feb 2;28(3):1465. doi: 10.3390/molecules28031465.
9
Roles of cytochrome P450 enzymes in pharmacology and toxicology: Past, present, and future.细胞色素 P450 酶在药理学和毒理学中的作用:过去、现在和未来。
Adv Pharmacol. 2022;95:1-47. doi: 10.1016/bs.apha.2021.12.001. Epub 2022 Jul 18.
10
In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.体外评价毛菊苣苷对人细胞色素 P450 同工酶的抑制潜力。
BMC Complement Med Ther. 2022 Feb 18;22(1):46. doi: 10.1186/s12906-022-03517-0.
在体 CYP 酶的抑制与诱导:更新
Arch Toxicol. 2020 Nov;94(11):3671-3722. doi: 10.1007/s00204-020-02936-7. Epub 2020 Oct 27.
4
Quantitative determination of human serum testosterone via isotope dilution ultra‑performance liquid chromatography tandem mass spectrometry.采用同位素稀释超高效液相色谱-串联质谱法定量测定人血清睾酮。
Mol Med Rep. 2020 Aug;22(2):1576-1582. doi: 10.3892/mmr.2020.11235. Epub 2020 Jun 15.
5
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.阿比特龙对 CYP17A1 的慢、紧结合抑制作用重新定义了其动力学选择性和给药方案。
J Pharmacol Exp Ther. 2020 Sep;374(3):438-451. doi: 10.1124/jpet.120.265868. Epub 2020 Jun 17.
6
Unexpected Differences between Two Closely Related Bacterial P450 Camphor Monooxygenases.两种密切相关的细菌 P450 单加氧酶之间的意外差异。
Biochemistry. 2020 Jul 28;59(29):2743-2750. doi: 10.1021/acs.biochem.0c00366. Epub 2020 Jul 15.
7
Linkage between Proximal and Distal Movements of P450cam Induced by Putidaredoxin.由假单胞菌氧化酶诱导的 P450cam 近侧和远侧运动之间的联系。
Biochemistry. 2020 Jun 2;59(21):2012-2021. doi: 10.1021/acs.biochem.0c00294. Epub 2020 May 14.
8
Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity.非甾体抑制剂奥曲酮和塞维特酮与人细胞色素 P450 17A1 的多步结合及其对酶活性抑制的相关性。
J Med Chem. 2020 Jun 25;63(12):6513-6522. doi: 10.1021/acs.jmedchem.9b01849. Epub 2020 Apr 9.
9
Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.使用两种半胱氨酸靶向亲电试剂对细胞色素 P450 3A4 时间依赖性抑制的机制研究。
Drug Metab Dispos. 2020 Jun;48(6):508-514. doi: 10.1124/dmd.119.089813. Epub 2020 Mar 19.
10
Designing around Structural Alerts in Drug Discovery.药物发现中的结构警报设计。
J Med Chem. 2020 Jun 25;63(12):6276-6302. doi: 10.1021/acs.jmedchem.9b00917. Epub 2019 Sep 17.